CN116507733A - 共表达cxcr4和il-10的间充质干细胞及其用途 - Google Patents

共表达cxcr4和il-10的间充质干细胞及其用途 Download PDF

Info

Publication number
CN116507733A
CN116507733A CN202180075229.XA CN202180075229A CN116507733A CN 116507733 A CN116507733 A CN 116507733A CN 202180075229 A CN202180075229 A CN 202180075229A CN 116507733 A CN116507733 A CN 116507733A
Authority
CN
China
Prior art keywords
mscs
cxcr4
cells
cell
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180075229.XA
Other languages
English (en)
Chinese (zh)
Inventor
罗萨里奥·赫瓦斯·萨尔塞多
达米安·加西亚·奥尔莫
马里亚诺·加西亚·阿兰茨
米里亚姆·荷南德·罗德里格斯
胡安·安东尼奥·布埃伦·龙赛罗
罗莎·玛丽亚·亚涅斯·冈萨雷斯
玛丽亚·费尔南德斯·加西亚
梅赛德斯·洛佩斯·桑塔拉
玛丽娜·英玛拉达·盖琳·费雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Network Research Consortium Center
Energy Environment And Technology Research Center Oamp
Himenez Diaz Health Research Foundation Institute
Original Assignee
Biomedical Network Research Consortium Center
Energy Environment And Technology Research Center Oamp
Himenez Diaz Health Research Foundation Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Network Research Consortium Center, Energy Environment And Technology Research Center Oamp, Himenez Diaz Health Research Foundation Institute filed Critical Biomedical Network Research Consortium Center
Publication of CN116507733A publication Critical patent/CN116507733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180075229.XA 2020-09-07 2021-09-07 共表达cxcr4和il-10的间充质干细胞及其用途 Pending CN116507733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382792.8 2020-09-07
EP20382792.8A EP3964265A1 (en) 2020-09-07 2020-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
PCT/EP2021/074612 WO2022049306A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Publications (1)

Publication Number Publication Date
CN116507733A true CN116507733A (zh) 2023-07-28

Family

ID=72473480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180075229.XA Pending CN116507733A (zh) 2020-09-07 2021-09-07 共表达cxcr4和il-10的间充质干细胞及其用途

Country Status (11)

Country Link
US (1) US20230398152A1 (enExample)
EP (2) EP3964265A1 (enExample)
JP (2) JP2023540599A (enExample)
KR (1) KR20230082622A (enExample)
CN (1) CN116507733A (enExample)
AU (1) AU2021337798A1 (enExample)
BR (1) BR112023004167A2 (enExample)
CA (1) CA3194344A1 (enExample)
MX (1) MX2023002741A (enExample)
SA (1) SA523442866B1 (enExample)
WO (1) WO2022049306A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN115927178A (zh) * 2022-11-17 2023-04-07 华夏源(上海)生物科技有限公司 一种检测间充质干细胞抑制b细胞分化为浆细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637856D1 (en) * 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
CA2566267A1 (en) * 2005-12-09 2007-06-09 University Health Network Thymidylate kinase mutants and uses thereof
CA2784861A1 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
EP3487991B1 (en) * 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
JP7493497B2 (ja) * 2018-06-19 2024-05-31 フォンダッツィオーネ・テレソン・エティエッセ 操作された樹状細胞の生産及びその使用

Also Published As

Publication number Publication date
CA3194344A1 (en) 2022-03-10
SA523442866B1 (ar) 2024-05-05
US20230398152A1 (en) 2023-12-14
MX2023002741A (es) 2023-05-26
JP2026082892A (ja) 2026-05-19
WO2022049306A1 (en) 2022-03-10
JP2023540599A (ja) 2023-09-25
KR20230082622A (ko) 2023-06-08
EP3964265A1 (en) 2022-03-09
AU2021337798A1 (en) 2023-05-18
EP4210834A1 (en) 2023-07-19
BR112023004167A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
US20230398152A1 (en) Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
JP5095403B2 (ja) 治療的応用法のための遺伝的に改変された細胞
KR101764643B1 (ko) 중간엽 줄기 세포의 용도
US20230226222A1 (en) Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
US10046011B2 (en) Compositions for inducing or suppressing an immune response
JP2012100670A (ja) 幹細胞をホーミングさせるためのｃｃｒリガンド
Liu et al. Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue
JP2010523496A (ja) 虚血障害の治療方法
CN104822384A (zh) 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
CN104010664A (zh) 用于治疗多发性硬化的apc介导的耐受诱导
Lian et al. In vivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin I synthase gene improves cardiac performance in mice
US9315558B2 (en) Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies
Sandovici et al. Adenovirus‐mediated interleukin‐13 gene therapy attenuates acute kidney allograft injury
CN103619342B (zh) 用于治疗肥胖症和/或代谢综合征的方法
KR20220084006A (ko) 세포성 및 체액성 면역을 유도하는 동종이계 t-세포 기반 hiv 백신
EP4021570A1 (en) Treatment of non-alcoholic steatohepatitis
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
KR20080096091A (ko) 면역반응 조절을 위한 케모카인 수용체 7의 신규한 용도
CN120924501A (zh) 双基因工程化的间充质干细胞及其应用
Gabay et al. Interleukin-18 and interleukin-18 binding protein balance: focus on IL-18BP production and IL-18 maturation in macrophage activation syndrome
Weiss The potential protective role of caveolin-1 in intestinal inflammation in experimental colitis
HK40008045A (en) Methods modulating immunoregulatory effect of stem cells
HK1217211A1 (zh) 調節幹細胞的免疫調節作用的方法
Strodthoff et al. CD3+ CD4-CD8-T Cells in Adipose Tissue-Implications for Type 2 Diabetes and Atherosclerosis?: 7

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination